The anti-FRα antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell death. (PubMed, Mol Cancer Ther) - Apr 28, 2025 - P1, P2/3 | "This improved activity with combination therapy was associated with increased tumoral infiltration of CD8+ T cells. In conclusion, the work presented here provides rationale for evaluating luveltamab tazevibulin in NSCLC either as monotherapy or in combination with immune checkpoint blockade."
Journal • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CALR • CD8 • FOLR1 • HMGB1
|
|
Alice Yam; Andrew McGeehan; Christine Cheng; Cristina L Abrahams; Cuong Tran; Danielle K Lewis; Gang Yin; Genevive Hernandez; Hans-Peter Gerber; Helena Kiefel; Jennifer Smith; Krishna Bajjuri; Mark Armanini; Millicent Embry; Rhoneil Pena; Robert Yuan; Sihong Zhou; Xiaofan Li
|